Hiding in Plain Sight? A Focus on Diagnosing and Addressing the Unmet Needs in Homozygous Familial Hypercholesterolemia
April 20, 2022|
Individuals with homozygous familial hypercholesterolemia (HOFH) are typically less responsive, or even unresponsive, to standard lipid-lowering therapies such as statins and PCSK9 inhibitors, and may benefit from treatment with other mechanisms of action.
This curriculum is designed to educate clinicians about the prevalence of heterozygous familial hypercholesterolemia (HeFH) and HOFH, the importance of screening for familial hypercholesterolemia (FH), as well as the benefits and limitations of therapies available for lipid management in patients with HOFH. Watch the recording here.